Pacira BioSciences announced solid first quarter 2026 financial results with a 5% revenue increase to $177 million, driven by growth across its product portfolio including EXPAREL, ZILRETTA, and iovera°. The company highlighted successful execution of its 5x30 strategy aimed at long-term value creation, with stock up over 30% since its launch. Pacira is urging shareholders to vote for its highly qualified board nominees to prevent activist investor DOMA Perpetual from disrupting its strategic plan, which includes cost cuts and an immediate sale. The company remains confident in its growth trajectory and pipeline advancements with key clinical readouts expected later in 2026.
In Austria, selling Bitcoin directly between private individuals is taxed the same as sales via crypto exchanges. The taxable event is the capital gain—the difference between sale proceeds and acquisition cost—with a 27.5% tax rate for Bitcoin acquir...
The U.S. SEC has approved Evernorth's registration, clearing the way for its $1 billion Nasdaq listing under the ticker XRPN through a merger with Armada Acquisition Corp. II. Evernorth plans to actively manage its XRP treasury to generate yield and ...
Amprius Technologies is benefiting from strong demand for drone batteries, reporting a 125.7% year-over-year revenue increase and improved gross margins. The company raised its 2026 revenue forecast to at least $140 million and aims for $600 million ...
INmune Bio is considered significantly undervalued with its treatment Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) driving a strong investment case. Ebstrocel offers systemic itch reduction, setting it apart from competitors like K...
PayPal's stock dropped sharply by 14.67% to $52.45 after Stripe and Advent withdrew their $60.50 per share acquisition offer, causing the company's market value to fall from $52.58 billion to $44.87 billion. This reversal ended the summer rally drive...
